TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20020107
Drug: 0.5 per
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 per thousand alcohol administration
Study: 17627745
Drug: Transdermal testosterone
Normalized name: testosterone Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal testosterone treatment (300 mcg/day)
Study: 9755360
Drug: mCPP (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: mCPP (0.5 mg/kg orally)
Study: 3925486
Drug: Naloxone (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (1.2 mg IV)
Study: 4917915
Drug: Monovalent inactivated
Normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monovalent inactivated vaccine of the Hong Kong strain of influenza A virus
Study: 4917915
Drug: Polyvalent vaccine
Normalized name: pneumococcal 23-polyvalent vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyvalent vaccine containing only pre‐1968 Asian viruses
Study: 4917915
Drug: Intranasal spray
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal spray of the Hong Kong vaccine in addition to injected Asian vaccine
Study: 29410606
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg lemon verbena extract once daily
Study: 26429636
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose CT screening
Study: 23633626
Drug: Neural Tissue
Normalized name: tissue respiratory factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neural Tissue Management (NTM) - brief education, manual therapy, and nerve gliding exercises for 4 treatments over 2 weeks
Study: 17313010
Drug: Simple electroacupuncture
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simple electroacupuncture or exercise therapy
Study: 9471669
Drug: Ranitidine, 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine, 150 mg at bedtime for 12 months
Study: 7920941
Drug: NO and
Normalized name: GLYCERYL MONO AND DICAPRYLOCAPRATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: NO and Pg E1 combination
Study: 3883738
Drug: Molsidomine 4
Normalized name: molsidomine 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Molsidomine 4 mg orally (single dose)
Study: 3883738
Drug: Molsidomine 4
Normalized name: molsidomine 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Molsidomine 4 mg orally (long-term treatment, 3 times daily for 3 weeks)
Study: 3883738
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy with digitalis and diuretics (Control)
Study: 30184031
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin D (50,000 U)
Study: 25420552
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein hydrolysate plus sucrose (0.4 g · kg(‐1) each)
Study: 25420552
Drug: Isocaloric sucrose
Normalized name: Sucrose
DrugBank: Sucrose (DB02772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isocaloric sucrose control (0.8 g · kg(‐1))
Study: 25420552
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein hydrolysate and sucrose (0.4 + 0.4 g · kg(‐1) · h(‐1)) with immediate ingestion
Study: 25420552
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein hydrolysate and sucrose (0.4 + 0.4 g · kg(‐1) · h(‐1)) with overnight ingestion
Study: 10624069
Drug: Esmolol (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol (500 micrograms/kg bolus followed by infusion of up to 100 micrograms/kg/min)
Study: 26598418
Drug: No sedative
Normalized name: MedActive Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: No sedative treatment
Study: 29785878
Drug: FFR-guided PCI
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FFR-guided PCI plus medical therapy
Study: 22484664
Drug: Nitrite therapy
Normalized name: Nitrite
DrugBank: Nitrite (DB12529)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrite therapy
Study: 22484664
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose nitrite infusion
Study: 8241229
Drug: Deflazacort, 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deflazacort, 1.5 mg/kg/day, tapered to 0.25 mg/kg/day after 2-3 weeks
Study: 8241229
Drug: Prednisone, 1
Normalized name: PredniSONE, 1 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone, 1 mg/kg/day, tapered to 0.15 mg/kg/day after 2-3 weeks
Study: 31259628
Drug: Reduced in-treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduced in-treatment systolic blood pressure (SBP)
Study: 31259628
Drug: Reduction in
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduction in in-treatment SBP
Study: 26063441
Drug: Propranolol (beta-blocker)
Normalized name: beta-Propranolol
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propranolol (beta-blocker) administered in a double-blind, placebo-controlled study
Study: 16523267
Drug: Liquorice gel
Normalized name: Liquorice
DrugBank: Licorice (DB10675)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquorice gel (control + 2.5% liquorice extract)
Study: 16523267
Drug: Control gel
Normalized name: SALICYLIC ACID 20 mg in 1 mL TOPICAL GEL [Walgreens Acne Control Gel]
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control gel (8% acid‐hydrolyzed corn starch, 25% maltitol syrup, water)
Study: 16523267
Drug: Liquorice gel
Normalized name: Liquorice
DrugBank: Licorice (DB10675)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquorice gel
Study: 12602644
Drug: Co-occurring substance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-occurring substance abuse, treatment nonadherence, and outpatient services intensity
Study: 7903326
Drug: ipsapirone 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ipsapirone 5 mg t.i.d.
Study: 7903326
Drug: ipsapirone 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: ipsapirone 10 mg t.i.d.
Study: 7903326
Drug: diazepam 5
Normalized name: diazepam 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: diazepam 5 mg t.i.d.
Study: 3936946
Drug: Chemotherapy (Mitomycin‐C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (Mitomycin‐C + FT 207)
Study: 26701357
Drug: BD FlowSmart
Normalized name: BD-111
DrugBank: BD-111 (DB18247)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BD FlowSmart infusion set
Study: 22349482
Drug: Caffeine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (5 mg/kg ingested on 2 separate days)
Study: 17342402
Drug: Empiric PPI
Normalized name: aspirin / codeine phosphate Oral Tablet [Empirin with Codeine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empiric PPI treatment
Study: 8195335
Drug: Human biosynthetic
Normalized name: Proinsulin biosynthetic human
DrugBank: Proinsulin human (DB17875)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human biosynthetic growth hormone (HGH; 12 IU/day)
Study: 2958398
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (ISDN) 10 mg sublingually
Study: 2958398
Drug: Nifedipine 20
Normalized name: nifedipine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 20 mg sublingually followed by Isosorbide dinitrate (ISDN) 10 mg
Study: 15653117
Drug: Xuezhikang 1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xuezhikang 1200 mg/day
Study: 15653117
Drug: Xuezhikang 2400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xuezhikang 2400 mg/day
Study: 10554570
Drug: Detection of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Detection of ICA antibodies
Study: 10554570
Drug: Detection of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Detection of anti-GAD antibodies
Study: 10554570
Drug: Detection of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Detection of IA-2 antibodies
Study: 10554570
Drug: Presence of
Normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presence of 2 types of antibodies
Study: 30712687
Drug: Part-time wear
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part-time wear of Twin-block appliance (12 hours daily)
Study: 30712687
Drug: Full-time wear
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-time wear of Twin-block appliance (22 hours daily)
Study: 28323044
Drug: Medium doses
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium doses of vitamin D (1600, 2400, 3200 IU)
Study: 28323044
Drug: Low doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low doses of vitamin D (400, 800 IU)
Study: 28323044
Drug: High doses
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High doses of vitamin D (4000, 4800 IU)
Study: 24820858
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg ginger, two times per day, 30 min before each dose of antiretroviral regimen for 14 days
Study: 24820858
Drug: Placebo, two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, two times per day, 30 min before each dose of antiretroviral regimen for 14 days
Study: 10580169
Drug: N-monomethyl-L-arginine (LNMMA)
Normalized name: .alpha.N-(methoxycarbonyl)-L-arginine
DrugBank: Tilarginine (DB11815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-monomethyl-L-arginine (LNMMA)
Study: 8174950
Drug: Cisapride (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride (10 mg twice daily)
Study: 3515333
Drug: Oral naproxen
Normalized name: naproxen Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral naproxen (250 mg per day for two weeks)
Study: 3515333
Drug: Local injection
Normalized name: Sclerosing agents for local injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local injection of betamethasone (6 mg in a long-acting form)
Study: 2893916
Drug: digoxin 0.125
Normalized name: digoxin 0.125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: digoxin 0.125 mg twice daily
Study: 26372401
Drug: D-cycloserine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-cycloserine (50 mg) administered after each of 10 CBT sessions
Study: 26372401
Drug: Placebo (PBO)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PBO) administered after each of 10 CBT sessions
Study: 26372401
Drug: D-cycloserine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-cycloserine (50 mg) with high homework compliance
Study: 21397483
Drug: Formoterol (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formoterol (12 μg, twice daily for 14 days)
Study: 21397483
Drug: Tiotropium (18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium (18 μg, once daily for 14 days)
Study: 21397483
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of Formoterol (200 μg)
Study: 21397483
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of Tiotropium
Study: 21397483
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of Salbutamol (200 μg)
Study: 10700672
Drug: PRED 40
Normalized name: A-MethaPred 40 MG Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRED 40 mg in the morning
Study: 9596864
Drug: 15‐methyl‐PGF2 alpha
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15‐methyl‐PGF2 alpha 0.100 mg
Study: 9596864
Drug: 15‐methyl‐PGF2 alpha
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15‐methyl‐PGF2 alpha 0.125 mg
Study: 9596864
Drug: 15‐methyl‐PGF2 alpha
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15‐methyl‐PGF2 alpha 0.200 mg
Study: 8404386
Drug: Transproctoscopic Doppler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transproctoscopic Doppler ultrasound followed by local injection treatment with 5 percent phenol almond oil
Study: 2948853
Drug: RA27/3 rubella
Approvals — FDA: no, EMA: no, PMDA: no
Description: RA27/3 rubella vaccine from Institut Merieux
Study: 2948853
Drug: RA27/3 rubella
Approvals — FDA: no, EMA: no, PMDA: no
Description: RA27/3 rubella vaccine from Wellcome
Study: 26242331
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no Epo treatment)
Study: 8412310
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion carboplatin 250 mg/m2 per day for 5 days and etoposide 150 mg/m2 per day for 5 days.
Study: 8412310
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion carboplatin 310 mg/m2 per day for 5 days and etoposide 150 mg/m2 per day for 5 days.
Study: 20683035
Drug: saracatinib 500
Normalized name: Saracatinib
DrugBank: Saracatinib (DB11805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: saracatinib 500 mg
Study: 20683035
Drug: saracatinib 125
Normalized name: Saracatinib
DrugBank: Saracatinib (DB11805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: saracatinib 125 mg for 14 days
Study: 12680790
Drug: WBRT (Whole
Approvals — FDA: no, EMA: no, PMDA: no
Description: WBRT (Whole Brain Radiation Therapy) alone
Study: 8904876
Drug: Anti-Tf receptor
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-Tf receptor antibody 42/6
Study: 8904876
Drug: Blockade of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blockade of Tf-mediated iron uptake with anti-Tf receptor antibody 42/6
Study: 1652265
Drug: pH-adjusted solution
Normalized name: PH-284
DrugBank: PH-284 (DB05452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: pH-adjusted solution of 2% mepivacaine with epinephrine
Study: 1652265
Drug: Standard commercial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard commercial preparation of 2% mepivacaine with epinephrine
Study: 28993335
Drug: Efavirenz in
Normalized name: Product containing efavirenz in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efavirenz in combination with Zidovudine-Lamivudine
Study: 28993335
Drug: Maraviroc in
Normalized name: Product containing maraviroc in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maraviroc in combination with Zidovudine-Lamivudine
Study: 25988766
Drug: Carbohydrate-electrolyte solution
Normalized name: CARBOHYDRATE/ELECTROLYTES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate-electrolyte solution (CES) 3mL·kg(‐1) body mass of a 6% CES every 20 min during exercise
Study: 21440749
Drug: Low-dose tacrolimus
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose tacrolimus (TAC; 4-6 ng/mL)
Study: 21440749
Drug: Sirolimus (SRL;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sirolimus (SRL; 6-10 ng/mL)
Study: 21440749
Drug: Low-dose tacrolimus
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose tacrolimus (TAC)
Study: 11704395
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg eniporide
Study: 11704395
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg eniporide
Study: 11704395
Drug: Overall eniporide
Normalized name: Teniposide
DrugBank: Teniposide (DB00444)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Overall eniporide treatment
Study: 7191310
Drug: Acemetacin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acemetacin (3 x 30 mg/d)
Study: 7191310
Drug: Indometacin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indometacin (3 x 50 mg/d)
Study: 31841699
Drug: BGF MDI
Normalized name: MDI-P
DrugBank: 3,4-Methylenedioxy-N-isopropylamphetamine (DB06112)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BGF MDI 320/18/9.6 μg
Study: 27749321
Drug: Atorvastatin 40
Normalized name: atorvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 40 mg/day vs 20 mg/day
Study: 27749321
Drug: Atorvastatin administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin administration
Study: 26407654
Drug: Simvastatin 20mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 20mg/day (added to both treatments)
Study: 22288485
Drug: FMUD+AM (375
Approvals — FDA: no, EMA: no, PMDA: no
Description: FMUD+AM (375 mg amoxicillin plus 250 mg metronidazole for 7 days)
Study: 9421099
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg itraconazole orally once a day for 5 days
Study: 3433371
Drug: Radiotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy plus weekly low-dose cisplatin
Study: 22986144
Drug: nab-paclitaxel (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: nab-paclitaxel (125 mg/m² IV over 30 minutes on days 1, 8, and 15 of each 28-day cycle)
Study: 26899862
Drug: Intravenous dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous dexamethasone (8 mg)
Study: 18516888
Drug: Spinal anesthesia
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal anesthesia with 1% hyperbaric lidocaine 1 ml (10 mg) (group L)
Study: 18516888
Drug: Propofol general
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol general anesthesia (1.0 mg x kg(‐1) injected at 180 mg x kg(‐1) x hr(‐1) followed by continuous infusion at 8 mg x kg(‐1) x hr(‐1) (group P)
Study: 18516888
Drug: Spinal anesthesia
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal anesthesia with 1% hyperbaric lidocaine (group L)
Study: 11790169
Drug: Itraconazole (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole (200 mg, twice daily for 6 months)
Study: 10086433
Drug: Cognitive-behavior therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavior therapy (stimulus control, sleep restriction, sleep hygiene, and cognitive therapy)
Study: 10086433
Drug: Pharmacotherapy (temazepam)
Normalized name: Temazepam
DrugBank: Temazepam acetate (DB14671)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmacotherapy (temazepam)
Study: 10086433
Drug: Combined behavioral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined behavioral and pharmacological therapy
Study: 1922223
Drug: Nifedipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (20 mg slow-release preparation every 8 hours)
Study: 30300047
Drug: 3 mg·kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg·kg‐1 caffeine
Study: 30300047
Drug: 1 or
Normalized name: G-1 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 or 2 mg·kg‐1 caffeine
Study: 25131925
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment by general practitioner (GP)
Study: 12324292
Drug: Threonine intake
Normalized name: Threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Threonine intake of 7 mg x kg(‐1) x d(‐1)
Study: 12324292
Drug: Threonine intake
Normalized name: Threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Threonine intake of 11 mg x kg(‐1) x d(‐1)
Study: 12324292
Drug: Threonine intake
Normalized name: Threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Threonine intake of 15 mg x kg(‐1) x d(‐1)
Study: 12324292
Drug: Threonine intake
Normalized name: Threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Threonine intake of 19 mg x kg(‐1) x d(‐1)
Study: 12324292
Drug: Threonine intake
Normalized name: Threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Threonine intake of 22 mg x kg(‐1) x d(‐1)
Study: 12324292
Drug: Threonine intake
Normalized name: Threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Threonine intake of 27 mg x kg(‐1) x d(‐1)
Study: 10756363
Drug: Aprotinin (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprotinin (high dose)
Study: 12539003
Drug: Aprotinin (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprotinin (low dose)
Study: 6991534
Drug: Codeine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Codeine (30 mg)
Study: 883811
Drug: Trimethoprim-sulfamethoxazole (TMP-SMZ)
Normalized name: sulfamethoxazole / trimethoprim
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim-sulfamethoxazole (TMP-SMZ) 960 mg TMP and 4800 mg SMZ
Study: 29951886
Drug: Metoprolol (47.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (47.5 mg once daily)
Study: 27802097
Drug: Oral oxandrolone
Normalized name: Oxandrolone
DrugBank: Oxandrolone (DB00621)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral oxandrolone (Ox) 0.06 mg/kg/d for 2 years
Study: 27802097
Drug: Oral oxandrolone
Normalized name: Oxandrolone
DrugBank: Oxandrolone (DB00621)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral oxandrolone (Ox)
Study: 26246443
Drug: Pharmacological modulation
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pharmacological modulation using selective antagonists for µ‐opioid, dopamine D3 receptor (DRD3), and neurokinin 1 (NK1) receptors (naltrexone, GSK598809, vofopitant/aprepitant) in a placebo-controlled, randomised, crossover design.
Study: 16554448
Drug: Methylprednisolone 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone 0.6 mg/kg ideal body weight
Study: 12929058
Drug: Ultrathin oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrathin oral (UO) EGD
Study: 9379783
Drug: Dotarizine 50
Normalized name: Dotarizine
DrugBank: Dotarizine (DB06446)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dotarizine 50 mg (single dose)
Study: 9379783
Drug: Dotarizine 100
Normalized name: Dotarizine
DrugBank: Dotarizine (DB06446)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dotarizine 100 mg (single dose)
Study: 9379783
Drug: Dotarizine 200
Normalized name: Dotarizine
DrugBank: Dotarizine (DB06446)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dotarizine 200 mg (single dose)
Study: 9379783
Drug: Dotarizine 50
Normalized name: Dotarizine
DrugBank: Dotarizine (DB06446)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dotarizine 50 mg (twice daily for 14 days)
Study: 1588379
Drug: AG plus
Normalized name: Alamag Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: AG plus HC (250 mg AG twice a day, 20 mg HC twice a day)